European heart journal
-
European heart journal · Aug 2015
Randomized Controlled Trial Multicenter Study Comparative StudyMarfan Sartan: a randomized, double-blind, placebo-controlled trial.
To evaluate the benefit of adding Losartan to baseline therapy in patients with Marfan syndrome (MFS). ⋯ Losartan was able to decrease blood pressure in patients with MFS but not to limit aortic dilatation during a 3-year period in patients >10 years old. β-Blocker therapy alone should therefore remain the standard first line therapy in these patients.
-
European heart journal · Aug 2015
Randomized Controlled Trial Multicenter Study Comparative StudyEffect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
The angiotensin-receptor-neprilysin inhibitor (ARNI) LCZ696 reduced cardiovascular deaths and all-cause mortality compared with enalapril in patients with chronic heart failure in the prospective comparison of ARNI with an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. To more completely understand the components of this mortality benefit, we examined the effect of LCZ696 on mode of death. ⋯ https://clinicaltrials.gov/, NCT01035255.